Corporate Restructuring, Recognitions, Drug Approvals, Mergers and Stock Price Movements - Research Report on Agilent,

Corporate Restructuring, Recognitions, Drug Approvals, Mergers and Stock Price
Movements - Research Report on Agilent, UnitedHealth, Onyx, Alexion, and Opko

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 24, 2013

NEW YORK, September 24, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Agilent
Technologies Inc. (NYSE: A), UnitedHealth Group Inc. (NYSE: UNH), Onyx
Pharmaceuticals Inc. (NASDAQ: ONXX), Alexion Pharmaceuticals, Inc. (NASDAQ:
ALXN), and Opko Health Inc. (NYSE: OPK). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Agilent Technologies Inc. Research Report

On September 19, 2013, Agilent Technologies Inc. (Agilent) announced that it
plans to separate into two publicly traded companies: one in life sciences,
diagnostics, and applied markets (LDA) that will keep the Agilent name, while
the other company will be made up of Agilent's portfolio of electronic
measurement (EM) products. Agilent stated that the transaction aims for
strategic and operational advancements and improvements of both businesses
while also allows management to focus specifically on the customers of their
respective companies. According to the Company, Agilent shareholders will
receive a pro rata distribution of shares in the new EM Company via tax-free
spinoff. The Company expects the transaction to be completed by the end of
2014, subject to the satisfaction of closing conditions. Agilent informed that
the spinoff will have effect on its guidance for FY 2013, though the Company
expects to incur one-time charges related to the transaction during the
periods preceding the separation, to be quantified at a later date. The Full
Research Report on Agilent Technologies Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: []


UnitedHealth Group Inc. Research Report

On September 19, 2013, UnitedHealth Group Inc. (UnitedHealth) announced that
the Association of State and Territorial Health Officials (ASTHO) and United
Health Foundation named the Minnesota Department of Health (MDH) as the 2013
winner of the America's Health Rankings Champion Award. According to United
Health, the award honors a state or territorial health department that uses
data from the rankings to improve its state's health outcomes, including
addressing health disparities, and to build relationships with local health
departments and other partners. Minnesota Commissioner of Health Edward
Ehlinger, M.D., MSPH, said, "The Minnesota Department of Health uses the
Rankings to inform and motivate our department programs and community partners
in a shared effort to make Minnesota the healthiest state possible." The Full
Research Report on UnitedHealth Group Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: []


Onyx Pharmaceuticals Inc. Research Report

On September 18, 2013, Onyx Pharmaceuticals Inc. (Onyx) announced that the
waiting period in connection with Amgen's proposed acquisition of Onyx, under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR),
was terminated early on September 18, 2013 by United States Federal Trade
Commission as against its prior scheduled date of September 23, 2013. Onyx
stated that the termination of the HSR meets one of the conditions to fulfill
the tender offer and amongst one of the other conditions that need to be
satisfied is a minimum tender of at least a majority of outstanding Onyx
shares on a fully diluted basis. According to Onyx, the tender offer under
which Amgen will acquire all of the outstanding shares of Onyx for $125 per
share in cash, is scheduled to expire at 12:00 midnight, New York City time,
on October 1, 2013, unless it is extended pursuant to, and in accordance with
the terms of the merger agreement between Amgen and Onyx. The Full Research
Report on Onyx Pharmaceuticals Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: []


Alexion Pharmaceuticals, Inc. Research Report

On September 13, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced that
the Ministry of Health, Labour and Welfare (MHLW) in Japan approved Soliris
(eculizumab) for the treatment of pediatric and adult patients with atypical
hemolytic uremic syndrome (aHUS), a life-threatening, ultra-rare disorder
which can progressively damage vital organs, leading to stroke, heart attack,
and kidney failure. According to Alexion, the drug has already secured
approval in Japan for the treatment of paroxysmal hemoglobinuria (PNH),
another severe and ultra-rare disease. Prof. Motoshi Hattori, Professor and
Director of the Department of Pediatric Nephrology, Tokyo Women's Medical
University of Tokyo Woman's UHP, said, "Soliris has been proven to have a
life-transforming impact on patients suffering from aHUS and represents a
significant step forward in the treatment of this devastating disease. Results
from clinical studies show that chronic Soliris treatment inhibits
complement-mediated TMA which is responsible for thrombosis, vital organ
failure, and other life-threatening manifestations of aHUS." The Company
expects that aHUS patients in Japan will commence treatment with Soliris
during Q4 2013. The Full Research Report on Alexion Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Opko Health Inc. Research Report

On September 19, 2013, Opko Health Inc.'s (Opko) stock closing price fell
slightly to $8.40, which is 0.9% lower than the previous day's closing price
of $8.48. Earlier, on August 30, 2013, Opko had announced that the Company's
3.0% Convertible Senior notes due by 2033 are convertible by holders of such
Notes into shares of the Company's Common Stock. On the day of this
announcement, Opko's shares closed at $9.24. The Full Research Report on Opko
Health Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA

SOURCE Investors' Reports

Contact: Kristi Saunders, +1-315-982-6420 (North America)
Press spacebar to pause and continue. Press esc to stop.